KIR3DL1 and acute myeloid leukemia: Killer immunoglobulin-like receptor-human leukocyte antigen (KIR-HLA) mismatched NK cells (median, 29 × 106/kg NK cells) infusions shown a significant expansion of KIR-mismatched NK cells (median, 5,800/mL of blood on day 14) could decrease relapse rates without increasing mortality in children with AML (121).